Sanofi Valuation
| SNYN Stock | MXN 991.38 27.38 2.84% |
At this time, the company appears to be fairly valued. Sanofi has a current Real Value of 968.11 per share. The regular price of the company is 991.38. Our model measures the value of Sanofi from inspecting the company fundamentals such as Return On Equity of 0.0959, shares outstanding of 2.47 B, and Operating Margin of 0.26 % as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Sanofi's price fluctuation is very steady at this time. Calculation of the real value of Sanofi is based on 3 months time horizon. Increasing Sanofi's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sanofi is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sanofi Stock. However, Sanofi's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 991.38 | Real 968.11 | Hype 991.38 |
The intrinsic value of Sanofi's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sanofi's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sanofi helps investors to forecast how Sanofi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sanofi more accurately as focusing exclusively on Sanofi's fundamentals will not take into account other important factors: Sanofi Total Value Analysis
Sanofi is at this time anticipated to have takeover price of 2.69 T with market capitalization of 2.22 T, debt of 14.86 B, and cash on hands of 8.73 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sanofi fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.69 T | 2.22 T | 14.86 B | 8.73 B |
Sanofi Investor Information
The company has price-to-book ratio of 1.61. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sanofi has Price/Earnings To Growth (PEG) ratio of 1.63. The entity recorded earning per share (EPS) of 56.31. The firm last dividend was issued on the 9th of May 2018. Sanofi is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Sanofi Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sanofi has an asset utilization ratio of 36.43 percent. This suggests that the Company is making 0.36 for each dollar of assets. An increasing asset utilization means that Sanofi is more efficient with each dollar of assets it utilizes for everyday operations.Sanofi Ownership Allocation
Sanofi shows a total of 2.47 Billion outstanding shares. About 89.74 % of Sanofi outstanding shares are held by general public with 10.26 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sanofi Profitability Analysis
The company reported the revenue of 45.39 B. Net Income was 6.72 B with profit before overhead, payroll, taxes, and interest of 31.69 B.About Sanofi Valuation
Our relative valuation model uses a comparative analysis of Sanofi. We calculate exposure to Sanofi's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sanofi's related companies.It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. SANOFI is traded on Mexico Stock Exchange in Mexico.
8 Steps to conduct Sanofi's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sanofi's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sanofi's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sanofi's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sanofi's revenue streams: Identify Sanofi's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sanofi's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sanofi's growth potential: Evaluate Sanofi's management, business model, and growth potential.
- Determine Sanofi's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sanofi's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Sanofi Stock Analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.